Cancer clinical trials in the region Bourgogne-Franche-Comté
219 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Prostate cancer
#NCT04916613
#2022-502425-18-00
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
49 recruiting sites
UNICANCER
Phase 3
Kidney cancer
#NCT06364631
#2023-503317-29-00
Required histologic types
Clear cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required IMDC scores
0
1 or 2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
36 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Lung cancer
#NCT06875310
#2024-515698-85-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3
Lung cancer
#NCT05692999
#2023-503481-23-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
28 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Colon cancer
Rectal cancer
#NCT05253651
#2024-514180-25-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
NRAS
17 recruiting sites
Seagen
Phase 3
Liver and bile duct cancer
#NCT06813976
Required histologic sub types
Ampullary carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
12 recruiting sites
CHU Dijon
Phase 3
Pancreas cancer
#NCT00268411
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
Radiotherapy
14 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 3
Stomach and esophageal cancer
#NCT06346392
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
AstraZeneca
Phase 3
Breast cancer
#NCT06393374
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Immunotherapy
Chemotherapy
Required previous treatments at advanced or metastatic stage
Surgery
Immunotherapy
Chemotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Antibody Drug Conjugates (ADC)
17 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Rectal cancer
#NCT06762405
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Radiotherapy
10 recruiting sites
CHU Dijon